Literature DB >> 19020794

Isn't the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008.

Hans Jürgen Möller1.   

Abstract

The metaanalysis of Kirsch (PLoS Med 5:e45, 2008) has (unfortunately!) attracted too much attention in the specialized press and especially in the lay press. Therefore, intensive critical commenting is necessary to not further alarm experts and health authorities as well as patients and family members. The specified commenting on these metaanalyses shall be prefaced with a short and critical commentary regarding the general significance of metaanalyses. The results of metaanalyses should not too naively be interpreted as the 'truth' as regards to the evidence based psychopharmacotherapy, but should be qualified in their significance due to principal methodological reasons Maier (Nervenarzt 78:1028-1036, 2007; Möller (Nervenarzt 78:1014-1027, 2007). Especially from these derived effect sizes should be interpreted carefully.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020794     DOI: 10.1007/s00406-008-0836-5

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  15 in total

1.  Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

Authors:  I M Anderson
Journal:  J Affect Disord       Date:  2000-04       Impact factor: 4.839

Review 2.  Design of clinical trials of antidepressants: should a placebo control arm be included?

Authors:  J Fritze; H J Möller
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

3.  STAR*D: what have we learned?

Authors:  A John Rush
Journal:  Am J Psychiatry       Date:  2007-02       Impact factor: 18.112

Review 4.  [Problems of evidence-based medicine in psychopharmacotherapy: problems of evidence grading and of the evidence basis for complex clinical decision making].

Authors:  H-J Möller; W Maier
Journal:  Nervenarzt       Date:  2007-09       Impact factor: 1.214

Review 5.  [Meta-analyses. A tool for maximizing therapy study evidence?].

Authors:  W Maier; H-J Möller
Journal:  Nervenarzt       Date:  2007-09       Impact factor: 1.214

Review 6.  Placebo-controlled studies in depression: necessary, ethical and feasible.

Authors:  David Baldwin; Karl Broich; Jürgen Fritze; Siegfried Kasper; Herman Westenberg; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2003-02       Impact factor: 5.270

Review 7.  Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities.

Authors:  Thomas C Baghai; Hans-Peter Volz; Hans-Jürgen Möller
Journal:  World J Biol Psychiatry       Date:  2006       Impact factor: 4.132

Review 8.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care.

Authors:  Michael Bauer; Tom Bschor; Andrea Pfennig; Peter C Whybrow; Jules Angst; Marcio Versiani; Hans-Jürgen Möller
Journal:  World J Biol Psychiatry       Date:  2007       Impact factor: 4.132

9.  Selective publication of antidepressant trials and its influence on apparent efficacy.

Authors:  Erick H Turner; Annette M Matthews; Eftihia Linardatos; Robert A Tell; Robert Rosenthal
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245

10.  Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration.

Authors:  Irving Kirsch; Brett J Deacon; Tania B Huedo-Medina; Alan Scoboria; Thomas J Moore; Blair T Johnson
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069

View more
  18 in total

1.  How close is evidence to truth in evidence-based treatment of mental disorders?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-22       Impact factor: 5.270

2.  [Efficiency of antidepressant therapy for patients with less severe depression].

Authors:  T C Baghai; H J Möller; S Nitschmann
Journal:  Internist (Berl)       Date:  2010-11       Impact factor: 0.743

3.  The public debate on psychotropic medication and changes in attitudes 1990-2011.

Authors:  Matthias C Angermeyer; Sandra Van der Auwera; Herbert Matschinger; Mauro G Carta; Sebastian E Baumeister; Georg Schomerus
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-11-28       Impact factor: 5.270

4.  EPA guidance on improving the image of psychiatry.

Authors:  A M Möller-Leimkühler; H-J Möller; W Maier; W Gaebel; P Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-02-13       Impact factor: 5.270

5.  [Unipolar depressive disorders].

Authors:  H-J Möller
Journal:  Nervenarzt       Date:  2009-05       Impact factor: 1.214

6.  Meta-analyses: a method to maximise the evidence from clinical studies?

Authors:  Wolfgang Maier; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02       Impact factor: 5.270

7.  [Core symptoms of depression].

Authors: 
Journal:  Nervenarzt       Date:  2009-11       Impact factor: 1.214

8.  Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations.

Authors:  Hans-Jürgen Möller; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02       Impact factor: 5.270

9.  Principle standards and problems regarding proof of efficacy in clinical psychopharmacology.

Authors:  Hans-Jürgen Möller; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02       Impact factor: 5.270

10.  General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.